The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
A clinical study was conducted to evaluate the efficacy and safety of the RCMOP regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large B-cell lymphoma who had incomplete remission.
Diffuse Large B-cell Lymphoma
DRUG: Mitoxantrone hydrochloride liposome injection|DRUG: RiTUXimab Injection|DRUG: Cyclophosphamid|DRUG: Vincristine|DRUG: Prednisolone
Objective response rate (ORR), To evaluate the efficacy of anti-tumor, At the end of cycle 2, At the end of cycle 4, (each cycle is 21 days)
Complete response rate (CRR), To evaluate the efficacy of anti-tumor, At the end of cycle 2, At the end of cycle 4; (each cycle is 21 days)|Duration of Response (DOR), To evaluate the efficacy of anti-tumor, CR or PR up to data cut-off (up to approximately 2 years)|Progression-free survival (PFS), To evaluate the efficacy of anti-tumor, Baseline up to data cut-off (up to approximately 2 years)|Overall survival (OS), To evaluate the efficacy of anti-tumor, Baseline up to data cut-off (up to approximately 2 years)|Treatment emergent adverse events (TEAEs), The incidence and severity of adverse events assessed by CTCAE v5.0, The first dose up to 21 or 28 days after the last dose
A clinical study was conducted to evaluate the efficacy and safety of the RCMOP regimen sequential therapy as a first-line treatment for patients with intermediate-to-high risk diffuse large B-cell lymphoma who had incomplete remission.